neobookRx

Prescription Writing

Standard Treatment Guidelines and Essential Medicines List for South Africa, Hospital Level, Adults 2019 Edition

Prescribers may initiate and/or maintain treatment with medicines as per the STGs in accordance with their scope of practice.

Medicines should be prescribed only when they are necessary for treatments following clear diagnosis. Not all patients or conditions need prescriptions for medicine. In certain conditions simple advice and general and supportive measures may be more suitable.

In all cases carefully consider the expected benefit of a prescribed medication against potential risks. This is especially important during pregnancy where the risk to both mother and foetus must be considered.

All prescriptions must:

  • be written legibly in ink by the prescriber with the full name, identification number and address of the patient, and signed with the date on the prescription form;
  • specify the age and, in the case of children, weight of the patient;
  • have prescriber details including the contact details i.e. name, qualification, registration number, address and contact telephone number; 
  • indicate the diagnosis on the prescription, where the patient has provided consent

In all prescriptions:

  • State the treatment regimen in full:
    • medicine name, strength and formulation
    • dose or dosage,
    • dose frequency,
    • duration of treatment,
      • e.g. amoxicillin 250 mg capsules, 8 hourly orally for 5 days.
  • Write the name of the medicine/preparation in full using the generic name.
  • Avoid abbreviations to reduce the risk of misinterpretation. Avoid the Greek mu (ų): write mcg as an abbreviation for micrograms.
  • Avoid unnecessary use of decimal points. If necessary, write a zero in front of the decimal point only, e.g. 2 mg not 2.0 mg or 0.5 mL and not .5 mL.
  • Avoid Greek and Roman frequency abbreviations that cause considerable confusion (qid, qod, tds, tid, etc). Instead either state the frequency in terms of hours (e.g. '8 hourly') or times per day in numerals (e.g. '3x/d').
  • In the case of “as required”, a minimum dose interval should be specified, e.g. every 4 hours as required.
  • Most monthly outpatient scripts for chronic medication are for 28 days; check that the patient will be able to access a repeat before the 28 days are completed.
  • Prescriptions for schedule 6 medicines are not repeatable, requiring to be issued monthly; and the quantity to be issued should be expressed in words.
  • After writing a script, check that the dose, dose units, route, frequency, and duration for each item is stated. Consider whether the number of items is too great to be practical for the patient, and check that there are no redundant items or potentially important drug interactions. Check that the script is dated and that the patient’s name, identification number and diagnosis/diagnostic code are on the prescription form. Only then should you sign the prescription and provide some other way for the pharmacy staff to identify the signature if there are problems (print your name, use a stamp, or use a prescriber number from your institution’s pharmacy).

Notes on specific medicines

ACE-inhibitor
Angioedema is a potentially serious complication of ACE-inhibitor treatment and if it occurs it is a contraindication to continued therapy or to re-challenge.
ACE-inhibitors and ARBs
ACE-inhibitors and ARBs can cause or exacerbate hyperkalaemia in chronic kidney disease (eGFR <60 mL/minute). Check the serum potassium before starting these medicines, and monitor serum potassium on therapy.
ACE-inhibitors and ARBs are contra-indicated in pregnancy.
Allopurinol
Contra-indicated in patients with eGFR <30 mL/minute.
Do not stop uric acid lowering drugs during an acute attack.
Amitriptyline + citalopram
Concomitant use of amitriptyline and citalopram may increase the risk of serotonin syndrome or neuroleptic malignant syndrome. Furthermore, there is a potential risk for QT prolongation.
Anti-epileptic medicines
Phenytoin, phenobarbitone and carbamazepine are potent enzyme inducing agents and should be used with caution with other medicines metabolised by the liver, especially warfarin, antiretrovirals, progestin subdermal implants and oral contraceptives.
Benzodiazepines
Benzodiazepines can cause respiratory depression.
Monitor patients closely as benzodiazepines can exacerbate an abnormal mental state or mask important neurological signs of deterioration.
Prolonged treatment with benzodiazepines often leads to tolerance and withdrawal symptoms if the medicine is discontinued abruptly.
Combination therapy with more than one benzodiazepine is not indicated.
ß–blockers 
ß–blockers should not be used in cocaine poisoning.
ß–blockers may cause bronchospasm in asthmatics.
Ciprofloxacin
Irrational use of quinolones contributes to the emergence of XDR-TB and potential masking of active TB.
Clindamycin
Clindamycin has good coverage against Gram positive organisms and anaerobes, so the addition of metronidazole is unnecessary.
Folic acid + vitamin B12
Anaemia megaloblastic: Give vitamin B12 and folic acid together until the test results are available as giving folic acid alone in patients with a B12 deficiency may precipitate a permanent neurological deficit.
Haloperidol
Dosing may vary according to clinical circumstances, e.g. lower doses in the elderly or where HIV infection or HIV-related dementia is known or suspected. In the frail and elderly patient, reduce the dose by half.
Lithium
Therapeutic drug monitoring is essential when using lithium. Clinical toxicity may occur even within the therapeutic range. Concomitant use of many medicines e.g. ACE-inhibitors, NSAIDs and diuretics may increase the risk of lithium toxicity.
Loperamide
Contraindicated in dysentery, acute non-inflammatory diarrhoea, antibiotic-associated diarrhoea and amoebic dyssentery; as it may result in toxic megacolon
Low molecular weight heparin (LMWH)
In morbid obesity dosing of LMWH should be individualised, in discussion with a specialist.
In renal failure (eGFR <30 mL/minute), the recommended dose of LMWH is 1 mg/kg/day. Pregnant women with mechanical prosthetic valves should not receive LMWH unless antifactor Xa levels can be monitored reliably weekly. Therapeutic range is pre-dosing level 0.6 units/mL and a 4-hour peak level of 1–1.2 units/mL.
Metformin
Metformin should be dose adjusted in renal impairment (eGFR: 30-60 mL/minute).
Metronidazole
The addition of metronidazole to amoxicillin/clavulanic acid is unnecessary as amoxicillin/clavulanic acid has adequate anaerobic cover.
Misoprostol (for TOP)
Misoprostol can cause uterine rupture in women with previous Caesarean sections and those of high parity. In these women use 200mcg of misoprostol or alternative methods such as extra-amniotic saline infusion without misoprostol. The dose of misoprostol, PV, decreases with increasing gestational age because of the risk of uterine rupture.
NSAIDs
Concomitant use of more than one NSAID has no additional clinical benefit and only increases toxicity. Chronic use of all NSAIDs is associated with varying degrees of gastrointestinal, renal and cardiovascular risks. Long-term use of NSAIDs should weigh potential benefits against these risks.
Oral diabetic agents
Oral diabetic agents should not be used in type 1 diabetes and used with caution in liver and renal impairment.
Insulin in the treatment of DKA
Potassium will fall on insulin treatment and patients with DKA have potassium depletion even if initial potassium is normal or high. It is therefore essential to monitor and replace potassium.
Antivenom
Never administer antivenom without being fully prepared to manage acute anaphylaxis.
Sodium chloride
Rapid correction of sodium, in hyponatraemia, may lead to central pontine myelinolysis, which is often irreversible. Sodium should be frequently monitored and increases should be <9mmol/L per day.
Spironolactone
Monitoring of sodium, potassium and renal function is essential in patients taking spironolactone. Avoid if eGFR < 30mL/minute.
SSRIs
Adolescents with depression may have an increased risk of suicidal ideation when initiated on SSRIs.
Streptokinase
Do not use heparin if streptokinase is given.
Sulphonylureas
Hypoglycaemia caused by a sulphonylurea can be prolonged. The patient should be hospitalised with an intravenous glucose infusion, and observed for at least 12 hours after glucose infusion has stopped.
Tricyclic antidepressants
Avoid in patients with cardiac disease and a high risk of overdose.
Testosterone
Screen hypogonadal men for prostate cancer before beginning testosterone replacement.
Unfractionated heparin
Evidence indicates that PTT monitoring is not necessary with weight based dosing of unfractionated heparin. However, in patients with morbid obesity and renal failure (eGFR < 30 mL/minute) unfractionated heparin should be used with PTT monitoring to maintain the PTT at 1.5 to 2.5 times the control. PTT should be taken 4 hours after SC dose.
Verapamil
Never give verapamil or adenosine IV to patients with a wide QRS tachycardia as this may precipitate ventricular fibrillation. In atrial flutter, do not use verapamil as it will not convert flutter to sinus rhythm and may cause serious hypotension.
Warfarin
Warfarin use requires regular INR monitoring and dose adjustment according to measured INR. See Prescribing Information for Specific Medicines

Standard Treatment Guidelines and Essential Medicines List for South Africa, Hospital Level, Adults 2019 Edition

Drugs mentioned

NeoHealth® ID 17374 · updated 9/15/2021